Bladder
An IO induction layer in front of trimodality-style preservation, read single-arm, so it sets a benchmark rather than a comparison against standard CRT or cystectomy.
INDIBLADE
ForStage II/III cT2-4aN0-2 MIBC, bladder-preservation candidates
78% at 2yr
0.67-0.9
TL;DR2yr bladder-intact EFS 78% (0.67-0.9) after induction ipi/nivo then chemoRT in cT2-4aN0-2 MIBC; 2yr OS 96% (0.91-1).
The RT-relevant gap is technique: the source gives no dose, fractionation, radiosensitizer, or whether the pelvic nodes were covered, and the cohort explicitly includes N1-2 and cT4a, so elective nodal coverage is exactly the parameter a reader needs and does not get. Bladder-intact EFS 78% at 2yr is the endpoint that gates preservation counselling.
In cT2-4aN0-2 MIBC where bladder preservation is already on the table, this supports discussing induction ipi/nivo before chemoradiation as investigational sequencing; it does not extend to cystectomy-eligible pts choosing surgery, nor to cT4b or M1 disease.
Technique is the missing variable: no dose, fractionation, or target volume, and with cT4a and N1-2 admitted, whether the pelvic nodes were treated is the parameter that decides whether 78% bladder-intact EFS transfers. Until that is published, this changes counselling tone, not planning.
Dual checkpoint blockade as induction, not concurrent or adjuvant, is the sequencing question here, and pts still completed chemoradiation afterwards. Cycles and dosing are not in source, so the regimen is not yet reproducible; 2yr OS 96% argues the sequence is at least deliverable.
Bladder-intact EFS 78% at 2yr bears on which cT2-4aN0-2 pts get offered preservation instead of upfront radical cystectomy. Salvage cystectomy rate is not reported in source, so the number that matters most for surgical planning, how many came to the OR anyway, is missing.
9 details
Single-arm bladder-preservation study of induction ipilimumab plus nivolumab followed by chemoradiation. Phase, N, number of sites and median follow-up are not reported in the source tweet; results are read out at 2 years.
Stage II/III muscle-invasive bladder cancer, cT2-4aN0-2. That range admits both node-positive and cT4a disease, a broader population than many bladder-preservation series. No further eligibility, performance status or baseline detail in source.
Induction ipilimumab + nivolumab, then chemoradiation. Dosing, number of induction cycles, and the concurrent radiosensitizer are not reported in source.
The chemoradiation component is named but not specified: no total dose, fractionation, technique, or target volume. Whether the cT4a and N1-2 pts received elective pelvic nodal coverage is unstated, which is the parameter that most gates transfer to another practice.
Primary read: 2yr bladder-intact event-free survival, 78% (0.67-0.9). 2yr OS 96% (0.91-1). Whether the trial prespecified bladder-intact EFS as its primary endpoint is not stated in source.
The 96% 2yr OS sits well above what an unselected cT2-4aN0-2 population would predict, which points at selection; the source reports no eligibility filter to judge that against. With no cystectomy or pathologic-response denominator reported, bladder-intact EFS cannot be separated into pts who never needed salvage vs pts who declined it.
The claim on offer is that adding induction ipi/nivo raises the ceiling of trimodality therapy, but a single arm cannot isolate the immunotherapy's contribution from the chemoradiation backbone. What it does establish is feasibility: pts got through induction dual checkpoint blockade and still completed CRT, with 2yr OS 96%.
Single-arm induction immunotherapy plus CRT with 2yr follow-up and wide CI; no randomised comparator against standard chemoradiation or cystectomy.
- Salvage cystectomy rate and pathologic response not reported
- Immunotherapy contribution over chemoradiation alone unproven
- Nodal coverage and RT dose for cT4a/N1-2 pts unstated
📚 Sources · 🐦 1 tweet
‼️ INDIBLADE: stage II/III (cT2-4aN0-2) MIBC -> induction ipilimumab plus nivolumab -> CRT
— NonsparseOncologist (@5_utr) June 17, 2026
2-year bladder-intact event-free survival is 78% (0.67−0.9) 🤩
2-year overall survival was 96% (0.91−1)
Lots of bladders can be potentially spared!https://t.co/LzTe72GYHD